AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Up 62.0% in March

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 153,264 shares, an increase of 62.0% from the February 26th total of 94,590 shares. Based on an average daily trading volume, of 194,526 shares, the days-to-cover ratio is presently 0.8 days. Approximately 4.7% of the company’s shares are short sold.

AIM ImmunoTech Trading Up 1.2%

Shares of AIM traded up $0.01 on Friday, reaching $0.70. The company’s stock had a trading volume of 304,630 shares, compared to its average volume of 9,888,321. AIM ImmunoTech has a twelve month low of $0.61 and a twelve month high of $36.00. The stock has a market capitalization of $2.30 million, a PE ratio of -0.07 and a beta of 1.26. The firm has a fifty day moving average of $0.98 and a 200-day moving average of $1.57.

Analysts Set New Price Targets

Separately, Zacks Research downgraded AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy”.

Institutional Investors Weigh In On AIM ImmunoTech

Institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC bought a new position in AIM ImmunoTech during the 2nd quarter valued at $87,000. DRW Securities LLC raised its holdings in shares of AIM ImmunoTech by 60.6% in the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after purchasing an additional 26,254 shares during the last quarter. Finally, Sabby Management LLC purchased a new stake in shares of AIM ImmunoTech in the third quarter valued at about $79,000. Institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.